Chapters

Transcript

Video

An Open-Label, Multicenter, Phase IIIb Study of Patients with Urinary Tract Carcinoma (UTC) (STRONG): Final Analysis for Fixed-Dose Durvalumab Monotherapy (Module A)

Bladder Cancer: Guru Sonpavde, MD details STRONG study results presented at ASCO #GU21? that find fixed-dose durvalumab monotherapy safe in patients previously treated for urinary tract carcinoma. Abstract 429


Published

February 19, 2021

Created by

Dana-Farber

Related Presenters

Guru P. Sonpavde, MD

Guru P. Sonpavde, MD

Medical Oncology

Guru P. Sonpavde, MD is the Bladder Cancer Director at Dana Farber Cancer Institute.

View full Profile